Ainos, Inc. (AIMD)
Ainos, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ainos, Inc. (AIMD) is a Biotechnology company based in US with a market capitalization of $7.1M. Revenue grew 498.9% year-over-year and free cash flow was negative at -$4.6M. This page tracks AIMD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 44 employees · IPO Jan 8, 2021
Valuation
Valuation & price
$1.75as of May 15, 2026· -58.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.93
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$7.1M
Market cap
498.9%
Revenue growth (YoY)
-3767.2%
Gross margin
-$4.6M
Free cash flow (USD)
$10.6M
Net debt
-55.1%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Ainos, Inc.'s market cap?
Ainos, Inc. (AIMD) has a market capitalization of $7.1M.
What is AIMD's P/E ratio?
A meaningful P/E ratio is not available for AIMD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is AIMD's price-to-book (P/B) ratio?
AIMD trades at 0.93 times book value per share.
Are insiders buying AIMD stock?
SEC Form 4 filings show no open-market insider buys at Ainos, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.